Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-11417 in relapsed or refractory mantle cell lymphoma
2022-500687-35-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of sonrotoclax in mantle cell lymphoma (MCL) (2 arms), sponsored by BeOne Medicines. Primary endpoints: Dose limiting toxicity, Treatment-emergent adverse events and serious adverse events and 2 more. Planned start Apr 2023; status: authorised.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-500687-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500687-35-00.